BACKGROUND: The need for accurate calculation of long-term care (LTC) pharmacies' costs to dispense (CTD) has become more important as payers have moved toward reimbursement models based on pharmacies' actual acquisition cost for drug products and the Centers for Medicare & Medicaid Services (CMS) has implemented requirements that LTC pharmacies must dispense prescriptions for certain branded drugs in 14-day-or-less quantities.
OBJECTIVES: To (a) calculate the average cost that the typical independently owned, closed-door LTC pharmacy currently incurs to dispense and deliver a prescription to the resident of a client LTC facility and (b) estimate how CMS-mandated changes to a 14-day-or-less dispensing cycle would affect the typical LTC pharmacy's average CTD.
METHODS:
The data requirements and measurement model were developed by academic researchers in consultation with an industry advisory committee of independent LTC pharmacy owners. A survey instrument was constructed to collect financial and operating data required to calculate the CTD. Surveys were distributed via 3 dissemination channels to approximately 1,000 independently owned, closed-door LTC pharmacies. The National Community Pharmacists Association mailed surveys to their LTC members; 3 major national wholesalers distributed surveys to their LTC customers through their newsletters; and 3 LTC group purchasing organizations distributed the surveys to their members through emails, newsletters, mailings, and/or regional meetings.
Each pharmacy's CTD was calculated by dividing total LTC dispensing-related costs by the total number of prescriptions dispensed. Dispensing-related costs included costs incurred to physically dispense and deliver prescriptions (e.g., dispensing pharmacists' and technicians' salaries and costs of medication containers) and costs incurred to support the dispensing function (e.g., salaries of delivery and medical records personnel). A model based on dispensing-related fixed, variable, and semivariable costs was developed to examine the impact of shorter dispensing cycles on LTC pharmacies' CTD. A prescription volume increase of 19% was assumed based on converting only solid oral branded drugs to short-cycle dispensing.
RESULTS: A diverse sample of 64 closed-door LTC pharmacies returned usable surveys. Sales from dispensing to LTC facilities accounted for more than 98% of total sales. Respondents indicated that they currently dispensed 23% of total doses in 14-day-or-less cycles and 76% in 28-31 day cycles. Most pharmacies used automated medication packaging technology, heat and cold package sealers, bar code systems, sterile compounding hoods, LTC printers or labelers, and electronic prescribing.
The median CTD was $13.54 with an interquartile range (25th to 75th percentiles) of $10.51 to $17.66. More than half of dispensing-related costs were from personnel expense, of which pharmacists and managers accounted for more than 40%. The results of the fixed and variable cost modeling suggested that converting solid oral brand-name drugs from 30-day to 14-day dispensing cycles would lower the median per prescription CTD to between $11.63 and $12.54, depending on the assumptions made about the effects of semivariable costs. However, this decrease in per prescription dispensing cost is dwarfed by an increase in total dispensing cost incurred by pharmacies that results from doubling the monthly volume of
• Long-term care (LTC) facilities have become a crucial part of the health care system. Recent estimates indicate there are 38,373 assisted living facilities serving 974,585 residents and 15,960 skilled nursing facilities serving 1.4 million residents in the United States.
• The pharmacies that serve LTC facilities are classified as either combination retail/LTC or closed-door. Combination retail/LTC pharmacies serve walk-in (retail) patients and those residing in LTC facilities. Closed-door pharmacies serve only patients in LTC facilities and similar settings. Within the closed-door category, pharmacies may be independently owned or part of large chains.
• Studies have documented the cost of dispensing a prescription in retail pharmacies, but little work has been done to calculate the cost of dispensing a prescription in LTC pharmacies. LTC pharmacies' costs are different because they provide a variety of services that are not routinely provided by retail pharmacies.
• Calculating the cost to dispense for LTC pharmacies has become more critical recently as a result of a move by third-party payers to reimburse pharmacies based on their actual acquisition costs and because, as of January 1, 2013, the Centers for Medicare & Medicaid Services has implemented a requirement that prescriptions for brand-name, solid dosage form prescriptions be dispensed to LTC patients in 14-day-or-less supplies.
Average Wholesale Price and is intended to approximate the pharmacy's acquisition cost for the drug product. The dispensing fee is intended to cover all operating costs incurred by the pharmacy to dispense the medication to patients in full compliance with all state and federal laws and provide a fair return on investment.
LTC Pharmacy Dispensing Costs
A retail community pharmacy's cost to dispense a conventional prescription to an ambulatory patient includes the following:
• costs of ordering, stocking, packaging, labeling, and dispensing the medication • costs incurred to perform all legally required administrative and professional services, including drug utilization review and patient counseling • appropriately allocated indirect and overhead costs including the cost of carrying accounts receivable from third-party prescription insurance programs LTC pharmacies incur additional dispensing-related costs for a variety of services that are not routinely provided by retail pharmacies to their ambulatory patients. 7, 8 These costs are as follows: • specialized packaging-prescriptions for LTC residents are typically dispensed in unit-of-use packaging, punch (e.g., "bingo") cards, cassettes, unit dose, or other special packaging required by facilities.
• delivery services-LTC pharmacies make regular deliveries to LTC facilities several times a day most (or all) days of the week and may make additional deliveries for medications needed in emergency situations.
• medication carts-LTC pharmacies deliver medications to facilities in packaging that is sized to fit into medication carts that are usually purchased by the pharmacy.
• 24-hour on-call pharmacy services-LTC pharmacies must have a pharmacist on call 24 hours a day or provide for emergency service through an outside contractor.
• parenteral medications-LTC pharmacies must be able to provide medications for parenteral administration to facilities. Such provision requires that pharmacies have access to specialized facilities, such as clean rooms and sterile hoods, for the preparation of intravenous prescriptions or provide for this service through an outside contractor.
• custom compounding-LTC pharmacies must be able to compound specialized drug formulations to meet the needs of patients who may not be able to take conventional oral dosage formulations.
• emergency medications-LTC pharmacies must provide "emergency" supplies of medications as well as systems for recording and charging medication used from emergency stock.
• reports, forms, and prescription ordering supplies-LTC pharmacies must provide reports, forms, and prescription A s the American population has aged, long-term care (LTC) facilities have become an increasingly important part of the health care system. These facilities provide assistance and supervision to people who are no longer able to live independently. The 2 most common types of LTC facilities are skilled nursing facilities (SNFs) and assisted living facilities (ALFs).
ALFs are designed to serve the "frail older person who is impaired and needs 24-hour monitoring or assistance with activities of daily living, such as dressing, bathing, and meal preparation and medication reminders."
1 ALF residents typically live in their own rooms or small apartments. The facilities provide meals, housekeeping, and laundry services. Most provide assistance with prescription medications, either by having nursing staff to actually administer residents' medications or by reminding residents when it is time to take their medications. SNFs serve patients with more substantial care needs. They provide "medical, nursing, social and rehabilitative services for older persons that require 24-hour nursing care and supervision." 3 They also provide and administer prescription drugs to residents. Almost half of SNF residents take 9 or more medications daily; only 13% take less than 5 medications daily. 4 As of 2010, there were 1.4 million residents in 15,960 SNFs in the United States. 5 The pharmacies that serve LTC facilities are classified as either combination retail/LTC or closed-door. Combination retail/LTC pharmacies serve both walk-in (retail) patients and those residing in LTC facilities. Closed-door pharmacies are closed to the general public; they serve only patients in LTC facilities and similar settings. Closed-door pharmacies are more similar to institutional pharmacies, such as those found in hospitals, than to retail pharmacies. There are approximately 1,200 closed-door pharmacies in the United States. 6 Within the closed-door category, pharmacies may be independently owned or part of large chains. The focus of this report is on independently owned, closed-door pharmacies.
Most public and private prescription benefit programs pay pharmacies on the basis of an estimated ingredient cost plus a flat dispensing fee. The ingredient cost is typically calculated as a discount on a published industry benchmark such as
• Our results suggested that converting oral, solid brand-name drugs from 30-day to 14-day dispensing cycles would lower the median per prescription CTD to between $11.63 and $12.54.
• The decrease in per prescription dispensing cost is dwarfed by an increase in total dispensing costs that results from doubling the monthly volume of short-cycle prescriptions.
What this study adds (continued)
ordering supplies to the facility. These include provider order forms, monthly management reports to assist the LTC facility in managing orders, medication administration records, and treatment administration records.
• LTC staff education and training-LTC pharmacies are required to provide ongoing in-service education and training programs to LTC facility staff.
The requirements to provide these additional services mean that LTC pharmacies incur a number of costs over and above those required of retail pharmacies to dispense prescriptions.
Historically, third-party payers underpaid pharmacies for the dispensing fee component but made up the difference by overpaying for the ingredient component. Over the past few years, a number of payers have begun to base reimbursement for ingredient costs on pharmacies' actual acquisition costs for the drug product. [9] [10] [11] [12] [13] [14] In these so-called cost-plus systems, a dispensing fee that reflects the full operating costs that are incurred to dispense prescriptions is critically important to the continued financial viability of participating pharmacies.
Another reason that accurate calculation of LTC pharmacy cost to dispense (CTD) has become increasingly urgent is that the Centers for Medicare & Medicaid Services (CMS) now requires LTC pharmacies to dispense prescriptions for solid oral branded drugs in 14-day-or-less quantities rather than the previous standard of a 30-day supply. CMS bases the new requirement on the belief that dispensing smaller quantities will significantly reduce waste-and cost-from unused medications. 15 While this savings may or may not occur, a certain effect of this change will be to increase the number of prescriptions that must be processed, dispensed, and delivered by LTC pharmacies. Because branded drugs represent about 20% of LTC prescriptions, this new requirement could significantly increase the number of monthly dispensing events, thereby increasing the cost pharmacies incur to provide a month's supply of branded medication to residents of LTC facilities. To the extent this increased expense occurs, dispensing fees paid to pharmacies must be adjusted to reflect the increased cost of dispensing solid oral branded drugs to LTC residents in shorter cycles.
The purpose of this project was to calculate the average cost that the typical independently owned, closed-door LTC pharmacy incurs to dispense and deliver a prescription for an LTC facility resident. There were 2 major objectives: (a) to calculate the CTD before the CMS changes were implemented and (b) to estimate the effect that the CMS-mandated change to a 14-day-or-less dispensing cycle will have on CTD.
■■ Methods Measurement Model and Survey Instrument
Numerous community pharmacy CTD studies have been conducted over the past several decades. As a result, broad consensus exists regarding the data that are required and the measurement model that should be used to accurately calculate the costs incurred by community pharmacies to dispense conventional prescriptions. Indeed, the calculation of a community pharmacy's CTD is sufficiently standardized that there is an Internet-based software application that can be used by pharmacy owners and managers to calculate their pharmacy's average cost to dispense a prescription. 16 Much less agreement exists regarding the data and measurement model required to accurately calculate the perprescription operating costs incurred by LTC pharmacies to dispense medications to residents of LTC facilities. This lack of consensus is partly the result of a dearth of published studies that have been conducted in LTC pharmacies and partly as a result of thorny definitional and methodological questions that have yet to be definitively answered, including a consensus definition of what constitutes a "prescription" in LTC pharmacy practice.
The data requirements and measurement model used in this study were developed by a team of experienced academic researchers who are recognized experts in community pharmacy financial analysis and supply chain cost accounting. The research team was assisted by an industry advisory committee consisting of 10 independent LTC pharmacy owners.
A survey instrument was constructed to collect financial and operating data required by the measurement model to calculate CTD among LTC pharmacies. A pilot test of the resulting survey instrument and instructions was subsequently conducted among members of the advisory committee, and several modifications were made before the instrument was distributed to the study sample.
Data Collection
The researchers were not able to identify a single comprehensive list of closed-door, independently owned LTC pharmacies. Rather, a number of different organizations had partial lists of these pharmacies (e.g., wholesaler customer lists or group purchasing organization member lists). Some of these organizations were not willing to share their lists but did agree to distribute survey instruments to their LTC pharmacy members or customers. As a result, survey instruments were distributed via 3 dissemination channels. First, the National Community Pharmacists Association (NCPA) mailed survey instruments directly to their LTC members. Second, 3 national wholesalers distributed survey instruments to their LTC customers through their respective newsletters. Third, 3 LTC group purchasing organizations (GPOs) distributed survey instruments to their members through emails, newsletters, mailings, and/ or regional meetings. NCPA mailed surveys to approximately 1,000 independently owned, closed-door LTC pharmacies beginning in May 2012. However, because other channels were also used to distribute survey instruments, with the probability that some pharmacies received survey instruments through more than one channel, we could not obtain a precise count of the number of pharmacies that ultimately received a survey.
LTC pharmacists were also urged to complete and return the survey through a variety of communications from NCPA including e-mail reminders, articles about the survey in NCPA's LTC newsletter and e-News, and at the town hall at the 2012 NCPA annual meeting. Surveys were also distributed at the regional meetings of one of the GPOs. In addition, several companies with LTC pharmacy interests shared information about the survey with their LTC pharmacy customers. Members of the NCPA LTC Division Advisory Board and members of the advisory committee personally contacted peers to encourage participation. Finally, a lottery for a free iPad was used to encourage participation.
Calculating the Cost to Dispense
An LTC pharmacy's cost to dispense a prescription is calculated as the total costs incurred to process, package, dispense, and deliver prescription medications to the residents of client LTC facilities divided by the total number of prescriptions dispensed to LTC facilities for the same 12-month operating period. For the purpose of this study, an LTC prescription was defined as "each occurrence of a medication that is dispensed and delivered to a LTC facility for use by a designated patient, irrespective of the dispensing cycle or number of doses that are contained in the packaging." For example, four 7-day cycles of a medication dispensed and delivered to an LTC resident during the month would be counted as 4 prescriptions while two 14-day cycles dispensed would be counted as 2 prescriptions.
The CTD for LTC pharmacies includes the direct costs of dispensing prescriptions and costs of activities that support dispensing-such as managers' salaries, billing personnel, and rent. The survey instrument asked pharmacies to report the direct and indirect costs of operating the pharmacy and the total number of prescriptions dispensed for the most recent fiscal year.
The costs of dispensing a prescription include both direct and indirect costs. Direct costs of dispensing are those that arise directly as a result of the dispensing activity. Direct costs would not be incurred by the pharmacy if the service were not provided. Examples of direct costs include medication carts, medication containers and labels, professional liability insurance, and dispensing-related equipment and automation. All direct dispensing-related costs were allocated to the calculated CTD in full.
Indirect costs are costs that support dispensing to LTC facilities as well as other activities in which the pharmacy is involved. Indirect costs are those that would be incurred even if the service in question were not provided. Examples of indirect costs incurred by LTC pharmacies include rent, utilities, insurance, and salaries. Accurate cost accounting requires that a fair share of indirect costs must be allocated to the CTD using some reasonable criterion. In most cases, the criterion is based on one of 3 rules: the proportion of hours personnel spend providing the service; the proportion of physical space required to provide the service; or the proportion of total sales the service accounts for in the business.
Salary expenses were allocated to the CTD based on the reported percentage of total work time that each personnel type spent in dispensing-related activities. The personnel types included in the study were managers, dispensing pharmacists, technicians, delivery personnel, billing personnel, medical records personnel, other dispensing support staff, and consultant pharmacists. Allocation of building mortgage or rent payments, utilities, maintenance and repair, and insurance costs was based on the ratio of the square footage that supported dispensing to total square footage of the pharmacy. The percentage of other indirect expenses was based on the ratio of sales of prescriptions to LTC facilities to total pharmacy sales.
The mean CTD was calculated for each pharmacy by dividing the total direct and indirect costs allocated to dispensing LTC prescriptions by the total number of prescriptions dispensed for the same 12-month period. The mean CTD calculated for each pharmacy was used to calculate the mean and median CTD across all responding pharmacies.
Our CTD analysis was based on a number of assumptions commonly used in the industry. We varied some of these assumptions in a sensitivity analysis to test their effects on the calculated CTD. The variations included the following:
• All salaries in the base case analysis were allocated to the costs of dispensing based on the ratio of hours worked in dispensing (or in support of dispensing) to total hours worked. In the first sensitivity analysis, we based the allocation on the ratio of LTC prescription sales to total pharmacy sales for managers, medical records personnel, billing personnel, and other dispensing staff. • In the second sensitivity analysis, the pharmacies with the highest and lowest CTD were dropped from the analysis to control for the influence of outliers. • In the third sensitivity analysis, the salary allocation based on the sales ratio was used, and the pharmacies with the lowest and highest CTD were dropped.
Estimating the Effect of Converting to a 14-Day-or-Less Dispensing Cycle on CTD
To examine the potential effect that requiring 14-day-or-less dispensing cycles would have on LTC pharmacies' average CTD, it is necessary to understand the distinction between fixed and variable costs. The distinction is not based on whether the cost varies per se, since all costs in a pharmacy will vary over time. Rather, what makes a cost variable in the accounting sense is that it varies in direct proportion to the volume of service being delivered, typically on a one-to-one basis. That is, for each additional unit of service or product that is produced, a variable cost will likewise increase. This concurrent variance typically results from a causal relationship that exists between the cost in question and delivery of the service. A familiar example of a direct variable cost in community pharmacy is the cost of prescription containers or packaging. The cost of this resource represents a direct variable cost of dispensing prescriptions because one of each is typically consumed each time a prescription is dispensed. Similarly, any materials or supplies that are routinely consumed during the delivery of a service would be considered a direct variable cost of service delivery.
In contrast, fixed costs are those for which the cost does not vary over the relevant range of volume. Returning to our prescription dispensing example, the most significant direct fixed cost of dispensing a prescription is personnel cost. Since pharmacy staff who are scheduled to work on a particular day will cost the practice the same amount of money whether an additional prescription is dispensed that day or not, their cost (i.e., wages, benefits, etc.) are generally considered to be a fixed cost of dispensing. Likewise, the cost of capital equipment that is used to deliver the service would be a fixed cost.
Naturally, if dispensing volume increased enough, a pharmacy would be forced to increase staff. Under such conditions, personnel could be considered to be a semivariable cost, a hybrid between fixed and variable costs that has characteristics of each. Like the fixed cost, a semivariable cost does not typically increase with changes in volume. However, given a sufficiently large change in volume, a semivariable cost will be affected. To continue the example with personnel cost, if prescription volume continues to increase, at some point it will be necessary to hire additional staff. The full cost of delivering a service is equal to the sum of variable, fixed, and semivariable costs:
Total Cost = Variable Costs + Fixed Costs + Semivariable Costs
To examine the effects of moving to a 14-day-or-less dispensing cycle, we classified LTC pharmacies' costs as fixed, variable, or semivariable and then modeled the projected effect of increasing prescription volume on pharmacies' costs to dispense. In classifying costs, it was necessary to consider the specific situation that pharmacies are in now that shortcycle dispensing is mandatory. In this situation, the volume of prescriptions dispensed will increase, but the number of facilities and patients served will not change. For our model, we assumed that the typical LTC pharmacy would experience a 19% increase in volume resulting from transitioning solid oral doses of branded drugs to a 14-day cycle. This assumption is based on the finding that the typical LTC pharmacy in our sample dispensed about 19% of prescriptions with solid oral brand-name drugs and the assumption that only these products would be converted to short-cycle dispensing.
For purposes of the model, we classified costs into 3 categories as described previously. Fixed costs consisted of costs that would not likely increase as a result of the increase in prescription volume resulting from a conversion to short-cycle dispensing. Examples included professional liability insurance, delivery expenses, and consultant pharmacist costs. In the case of delivery services, we conservatively assumed that most LTC pharmacies are already making frequent deliveries to client facilities for such things as starter doses or new Costs Assigned to Fixed, Variable, and Semivariable Cost Categories majority of doses was dispensed in single-dose blister (65.5%) or multidose blister (10.9%) packaging (Table 1) .
The typical pharmacy in our sample had annual sales of $16,638,363 (SD = $14,171,111). Sales from dispensing to LTC facilities accounted for more than 98% of total sales. Medicare Part D was the largest payer, accounting for an average of 47% of all prescriptions dispensed (Table 1) .
A majority of pharmacies used automated package-filling technology, heat and cold package sealers, bar code systems, sterile compounding hoods, LTC printers or labelers, and electronic prescribing. Remote automated dispensing cabinets, automated infusion technology, and integrated voice response systems were used by less than 25% of respondent pharmacies (Table 1) . residents, so a conversion from a 28-to 31-day supply to a 14-day supply would not require additional delivery costs. Variable costs included those costs that would likely increase in direct proportion to the increase in prescription volume. Examples included medication containers and labels and third-party program expenses. The third category, semivariable costs, includes costs that would probably not increase in response to a small increase in volume, but would increase in response to large increases in volume. Examples include dispensing pharmacists' salaries, technicians' salaries, and wastereducing technologies. A complete list of costs in each category is shown in Figure 1 .
Our model assumed that an increase in prescription volume would have no effect on fixed costs and would induce a proportional one-to-one change in variable costs. The effect that an increase in volume may have on semivariable costs will vary across pharmacies. Pharmacies that are operating close to capacity will realize increases in semivariable costs at relatively small increases in volume; those that have excess capacity will not realize increases in semivariable costs until they experience larger increases in volume. Because of the indeterminate effect that an increase in volume may have on semivariable costs, we applied a sensitivity analysis to the model that allowed for scenarios in which a 19% increase in prescription volume resulted in increases in semivariable costs of between 0% and 19%.
■■ Results

Responding Pharmacies
A total of 64 usable surveys were completed and returned. Surveys were returned from 30 different states representing all geographic regions of the country, and from rural (12.5%), small town (29.7%), suburban (35.9%), and urban locations (21.9%). Of the 64 respondents, 35 (54.7%) were part of multipharmacy organizations. Of these, 26 (74.2%) had a central office.
The typical LTC pharmacy occupied 7,644 square feet of space, had been open for 12.8 years, operated 6 days and 69 hours per week, and delivered 6 days per week. The typical LTC pharmacy serviced a mean of 91 (standard deviation [SD] = 124) facilities and 2,975 (SD = 3,392) beds.
Prescriptions and Dispensing
The typical responding LTC pharmacy dispensed 406,386 (SD = 436,566) prescriptions during the most recent fiscal year. Of these, 23.0% were for branded products, 67.1% were for generics, and 9.9% were for nonprescription drugs. A total of 81.8% were for solid oral dosage forms, 3.8% were for compounded prescriptions, and 14.4% were for other dosage forms (e.g., topical, ophthalmic, otic, etc.).
About 21% of total doses were dispensed in 14-day-or-less cycles; 77% were dispensed in 28-to 31-day cycles; and the remainder was dispensed in cycles of other durations. The or per prescription, cost and because the typical LTC pharmacy has a substantial amount of fixed and semivariable costs. In calculating the CTD, the numerator represents total dispensing-related costs and the denominator is the total number of prescriptions dispensed. A 19% increase in prescription volume would increase the number of prescriptions dispensed by 19%. The pharmacy's variable costs, such as the costs of prescription labels and containers, would also increase by 19%. However, fixed costs, such as insurance and management salaries, would not increase, and semivariable costs, such as pharmacist and technician salaries, might not increase. As a
Cost to Dispense
The median CTD was $13.54 and the 25th and 75th percentiles were $10.51 and $17.66. The mean CTD was $14.05. More than half (53.1%) of dispensing-related costs were from personnel expenses (Figure 2) . Dispensing pharmacists and managers accounted for more than 40% of personnel expenses (Figure 3) .
The results of the sensitivity analysis indicated that the estimated CTD values were robust to the assumptions we made. Across the base case and the 3 variations, the mean CTD ranged from $13.76 to $14.05 and the median was $13.54 in all cases.
Effects of Converting to 14-Day Cycle
The median CTD for the base case was $13.54. The results of our model based on fixed and variable costs indicated that a 19% increase in prescription volume would lower the median CTD to $11.63 if there were no increases in semivariable costs and to $12.55 if semivariable costs increased by 19% (i.e., in direct proportion to the change in prescription volume). The interquartile ranges were $9.13 to $15.08, assuming no increase in semivariable costs, and $9.58 to $16.05, assuming the change in semivariable cost was proportionate to the change in prescription volume.
■■ Discussion
The objectives of this study were to calculate the CTD for a prescription in an LTC pharmacy before the implementation of CMS-mandated short-cycle dispensing that went into effect on January 1, 2013, and to estimate the effects that implementing a mandatory 14-day-or-less dispensing cycle for solid oral branded drugs would have on this cost.
The median CTD for LTC pharmacies in our sample was $13.54. Fifty percent of responding LTC pharmacies' CTD values were within $4.12 of the median value. We examined the sensitivity of the CTD to changes in a number of assumptions on which our dispensing calculation was based. To do this, we recalculated the CTD after (a) dropping outliers, (b) using a different basis for assigning personnel costs to dispensing costs, and (c) making both of these changes simultaneously. These changes had no effect on the calculated median CTD. This lack of effect increases the confidence that one can place in our results.
A model based on fixed and variable costs indicated that a 19% increase in prescription volume resulting from the switch of solid oral branded products from a 30-day to a 14-day dispensing cycle would lower the median CTD per prescription from $13.54 to between $11.63 and $12.54, a maximum decrease of $1.91. The size of the decrease depends on the extent to which an increase in prescription volume increases semivariable costs. The increase in volume would reduce the pharmacy's CTD because the CTD is an average, Indirect expenses included the allocated portions of annual costs of computer hardware and software, postage and delivery, telephone, other equipment, depreciation on the building and leasehold, depreciation on computer and other equipment, building rent or mortgage payments, utilities, maintenance and repairs, insurance, bad debt, advertising, office supplies, bank and credit card fees, accounting and legal expenses, security, taxes, and miscellaneous.
Direct expenses included after-hours pharmacist services, medication containers and labels, professional liability insurance, pharmacy licenses and permits, dues and subscriptions, expenses related to participation in third-party prescription programs, and depreciation on medication carts, delivery vehicles, and waste reducing technologies. Other consultant pharmacist costs included nonpersonnel expenses such as mileage, meals, and insurance. result, the denominator of the CTD calculation would increase by 19% while the numerator would increase by less than 19%. This would result in a lower CTD. The greater the pharmacy's fixed costs (compared with variable costs), the greater would be the decrease in CTD. Stated differently, as prescription volume increases, the pharmacy is able to operate more efficiently; it can therefore dispense more prescriptions without a proportionate increase in its costs. However, the decrease in per prescription dispensing costs that results from switching to a 14-day supply is dwarfed by the increase in total dispensing that results from doubling the volume of short-cycle prescriptions dispensed.
As discussed earlier, increases in volume would not affect the CTD in exactly this way across all possible increases in volume. At some point, pharmacies would be forced to add dispensing pharmacists and technicians to handle the increase in volume. At sufficiently large increases in volume, the pharmacy might even have to hire additional managers or move to a larger physical space.
The wide variability in the CTD among sample pharmacies affects these estimates. While the median CTD was $13.54, the 25th and 75th percentiles were $10.51 and $17.66. The variability is likely due, at least in part, to the high degree of customization that characterizes the services that independently owned LTC pharmacies provide to clients. Further, our model of the effects of increased volume was made for a "typical" pharmacy and was based on a number of assumptions. Different pharmacies have different cost structures and, therefore, will be affected to different degrees by increases in volume.
Our estimates assume that the CTD is incurred for every dispensing event. The median CTD is $13.54 per prescription. We have estimated that if prescription volume increased 19% as a result of transitioning solid oral branded prescriptions to 14-day cycles the CTD would decrease to $11.63. But the CTD would be incurred twice per month for maintenance medications. To state the calculation another way, if the patient's monthly supply of the drug is dispensed as one 30-day cycle, then the pharmacy's total cost of dispensing the drug for the month is $13.54. However, if the patient's monthly supply is dispensed as two 14-day cycles, then the total cost of dispensing the drug would be at least $11.63 for each prescription dispensed, or a total of $23.26. That is, while there are modest efficiencies created by reducing the days supply that is dispensed in short cycles, the modest cost savings created by these efficiencies are dwarfed by the increased costs that result from doubling the number of prescriptions that must be dispensed.
This information should be useful for pharmacies and thirdparty payers when negotiating reimbursement rates. As indicated earlier, a number of payers now reimburse pharmacies for ingredient costs based on the pharmacies' actual acquisition costs. This reimbursement means that the gross profit that pharmacies historically earned by purchasing drugs at prices lower than those they are reimbursed by payers is eliminated. In this situation, it is necessary that dispensing fees cover pharmacies' full dispensing costs. To set equitable and sustainable fees, pharmacies and payers must have accurate information about dispensing costs.
In the Medicare Part D program, the change to a 14-day dispensing cycle has increased pharmacies' costs of dispensing a month's supply of medications. The information from this study should better allow both LTC pharmacies and payers to recognize the incremental dispensing costs this increase has created for pharmacies. Pharmacies and payers can use this information to negotiate equitable and sustainable dispensing fees. The information from this study indicates that the negotiation should include both the level of the fee and whether the fee is paid on a per-prescription or per-month basis. Organizations representing LTC pharmacies, such as NCPA's LTC Division, could use the information from this study to advocate for fair and adequate dispensing fees with payers, CMS, and Congress.
CMS has recognized that the switch to 14-day cycles will increase pharmacies' dispensing costs, and it has stated that "dispensing fees should take into consideration the number of dispensing events in a billing cycle." 15 However, pharmacy reimbursements in the Part D program are set by private negotiations between pharmacies and payers, and CMS is prohibited from interfering with these negotiations. As a result, CMS cannot require increases in dispensing fees. However, while CMS does not currently have the authority to set dispensing fees, Congress could legislate such authority as it has in the Medicaid program. That may represent the best option available to LTC pharmacies if payers are unwilling to adjust dispensing fees accordingly.
Limitations
The single greatest threat to the external validity of any survey is response rate and a limitation of our study is the relatively limited number of responses in comparison to the size of the population. The primary concern with a relatively low response rate is that results may not be representative of the population from which they were drawn, i.e., closed-door, independently owned LTC pharmacies. While a legitimate concern, we believe this limitation is somewhat attenuated by having received responses from pharmacies in 30 states, including rural, urban, suburban, and small town locations, and from pharmacies dispensing relatively small to very large numbers of prescriptions. The response rate may have been low because of the length of the survey and the time required to complete it. 17 Additionally, a CTD survey requests highly sensitive financial information that many pharmacies are reluctant to share.
Another limitation of this study is that the data were selfreported and, lacking audit authority, the authors were unable to validate their accuracy. We believe this limitation was minimized in our study because survey questions required respondents to report data commonly found on income tax returns and common operating reports. Although this requirement does not prevent a respondent from consciously misrepresenting data, it does tend to reduce the possibility of inadvertent misreporting. In addition, the researchers applied a variety of internal audits to ensure the data were internally consistent and reasonable.
A final limitation of the study is that an LTC pharmacy's CTD can vary over the course of the year. Because the CTD is an average, or per prescription, cost, and because the typical LTC pharmacy has a substantial amount of fixed and semivariable costs, the CTD is sensitive to changes in volume. Compared with retail community pharmacies, LTC pharmacies can realize significant changes in volume during any given year as a result of losing or adding LTC facilities. As a result of these fluctuating volumes, the CTD can change over the course of the year.
■■ Conclusions
Our results, based on a diverse sample of 64 closed-door LTC pharmacies, indicated a median CTD of $13.54. The effects of moving to a shorter cycle, by increasing the number of prescriptions dispensed, would reduce pharmacies' average perprescription CTD. Our results indicated that the median CTD would be, at minimum, $11.63 if pharmacies only transitioned solid oral branded prescriptions to shorter cycles. However, this decrease in per-prescription dispensing costs is more than offset by the increase in total dispensing costs that result from dramatically increasing the volume of prescriptions that must be dispensed each month. As a result, the typical LTC pharmacy in our sample would incur a median CTD of $13.54 for dispensing a month's supply of a medication, or at least $23.26 if the medication were dispensed in two 14-day cycles (a median CTD of $11.63 for each cycle dispensed).
